OncoMatch

OncoMatch/Clinical Trials/NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Is NCT05797168 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for ovarian cancer.

Phase 1/2RecruitingAstraZenecaNCT05797168Data as of Sep 2026Location: International · 12 countries

Treatment: Torvutatug samrotecan · Saruparib · Bevacizumab · Carboplatin · Palacaparib · PembrolizumabThis research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Pembrolizumab

Targeted therapy

SaruparibBevacizumabPalacaparib

Chemotherapy

Carboplatin

Other

Torvutatug samrotecan

Cancer type

Ovarian Cancer

Non-Small Cell Lung Carcinoma

Endometrial Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 130

Prior therapy

Must have received: adequate prior therapy for tumor type and stage

Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy.

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ and marrow function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Duarte, California
  • Research Site · Irvine, California
  • Research Site · La Jolla, California
  • Research Site · Aurora, Colorado
  • Research Site · Louisville, Kentucky

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05797168 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received adequate prior therapy for tumor type and stage.

Is there an age limit?

Yes. Patients must be 130 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify